• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dance Biopharm Holdings raises $20.5M in private investment financing round

May 3, 2019 By Danielle Kirsh

Dance BiopharmPrivately-held Dance Biopharm said yesterday that it has completed a private equity financing round to secure about $20.5 million in gross proceeds.

The financing round was insider-only with a number of institutional and individual accredited investors participating. Molex Ventures made a substantial equity investment in Dance Biopharm, according to the company. Molex has been involved in the development of Dance Biopharm’s Dance 501 inhalable insulin device that is designed to offer better management of diabetes treatment and other biologic therapies.

“This round of financing comes at an inflection point for Dance as we make the preparations to embark on the pivotal trials for Dance 501, our flagship soft mist inhaled insulin product, and advance our pipeline assets toward human clinical trials,” CEO of Dance Anne Whitaker said in a press release.

The money from the financing round will go toward funding the manufacturing of the insulin and devices for Phase 3 registration studies for the company’s Dance 501, IND-enabling studies for Dance 601, a GLP-1 analog, organizational preparation for carrying out the studies and other corporate purposes.

Dance 501 is a preservative-free formulation of inhaled recombinant human insulin that is delivered through a smart, handheld soft mist device. It enables convenient and confident delivery of insulin into the lungs in a few breaths, according to the Dance Biopharm. The company plans to start a global, Phase 3 clinical development program with the device in people who have Type 1 and Type 2 diabetes by mid-2020.

“We are pleased to have made an additional investment in Dance as they advance the development and use of inhaled biologics in the form of smart, needle-free medical devices for chronic medical conditions. We believe that Dance is making important headway in the development and commercialization of a simple and cost-effective biologics delivery platform built on leading-edge technologies,” Lily Yeung, VP of Molex Ventures, said.

SternAegis Ventures was the exclusive agent for the financing round.

Filed Under: Diabetes, Funding Roundup Tagged With: dancebiopharm

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at dkirsh@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS